What is the market's earnings forecast for Bio-Rad Laboratories B next quarter?

What factors drove the changes in Bio-Rad Laboratories B's revenue and profit?

What does Bio-Rad Laboratories B do and what are its main business segments?

What were the key takeaways from Bio-Rad Laboratories B's earnings call?

What is the revenue and EPS growth rate for Bio-Rad Laboratories B year over year?

Did Bio-Rad Laboratories B beat or miss consensus estimates last quarter?

What is Bio-Rad Laboratories B's latest dividend and current dividend yield?

What were the key takeaways from Bio-Rad Laboratories B’s earnings call?

- **Q3 Revenue Stable**: $653 million (+0.5% YoY), with process chromatography up 17% but offset by softness in academic research.
- **Margins Improved**: Non-GAAP operating margin 11.8% (vs. 11.3% YoY), driven by cost control.
- **Strategic Growth**: ddPCR partnerships and QX platform adoption show early momentum, with Q4 instrument shipments expected to rise.
- **China Risks**: Reimbursement cuts and macro weakness weigh on diagnostics, but quality controls portfolio provides resilience.
- **2026 Outlook**: High single-digit growth for process chromatography; academic funding recovery uncertain.

**【Management Opening Remarks】**
- Yong Chung provided an overview of the call, emphasizing forward-looking statements and non-GAAP financial measures. The company highlighted the exclusion of Sartorius AG equity value to focus on operational performance.

**【CEO & COO Commentary】**
- **Q3 Performance**: Revenue growth was modest, with challenges in academic research and biotech funding. Clinical Diagnostics faced headwinds from China's reimbursement rate cuts.
- **Strategic Initiatives**: Progress in ddPCR, including global sales training on new QX platforms and partnerships with Gencurix and Biodesix, showed early customer receptivity.
- **Operational Efficiency**: Cost management and lean initiatives drove margin outperformance, with operating margin improving to 11.8% (non-GAAP).

**【CFO Financial Commentary】**
- **Revenue**: Q3 net sales of $653 million (+0.5% YoY, -1.7% currency-neutral) reflected flat Life Science and 0.6% Clinical Diagnostics growth. Process chromatography grew 17% YoY but expected to decline in Q4.
- **Margins**: GAAP gross margin 52.6% (-220bps YoY) due to material costs. Non-GAAP operating margin 11.8% (vs. 11.3% YoY), driven by cost control.
- **Cash Flow**: Free cash flow $89 million (Q3) and $256 million (YTD), with full-year guidance of $310-330 million.
- **Share Buybacks**: $53 million spent in Q3, with $285 million remaining under the program.

**【Q&A Highlights】**
- **Q4 Outlook**: Modest Life Science improvement, China reimbursement headwind annualizing, and ddPCR instrument demand expected to rebound.
- **China Risks**: Soft macro environment may persist, but quality controls portfolio growth offsets some pressure.
- **2026 Guidance**: High single-digit growth for process chromatography; academic funding cautious due to NIH budget uncertainty.
- **ddPCR Progress**: Strong pipeline and customer interest, with Q4 instrument shipments expected to accelerate.


Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript

- **Revenue growth acceleration**: Q2 2025 revenue up 2.1% YoY to $652M, driven by 20% process chromatography pull-forward and ddPCR portfolio expansion. 
- **ddPCR portfolio expansion**: QX700 Series and QX Continuum platforms launched post-Stilla acquisition, adding $15M annualized revenue. 
- **China Diagnostics resilience**: Stable outside China despite 3.7% diabetes testing decline. 
- **Tariff headwind reduction**: 30-40bps vs prior 130bps, manufacturing flexibility mitigating risks. 
- **FY25 guidance upgrade**: 0-1% revenue growth (vs -3% to 0% prior), 12-13% operating margin (vs 10-12% prior). 
- **Free cash flow strength**: $71M Q2, targeting $310-330M FY25. 


**【CEO Summary Section】**
- Q2 2025 revenue grew 2.1% YoY to $652 million, driven by strong process chromatography sales (+20% YoY pull-forward) and ddPCR portfolio expansion. Life Sciences segment grew 4.9% YoY, while Diagnostics remained stable. 
- ddPCR portfolio now includes rebranded QX700 Series and QX Continuum platforms, with Stilla acquisition adding $15 million in annualized revenue. Consumables demand in academia proved more resilient than expected. 
- China Diagnostics growth offset by 3.7% decline in China diabetes testing due to reimbursement cuts. Global tariff headwinds reduced to 30-40bps vs prior 130bps estimate. 
- FY25 guidance updated to 0-1% revenue growth (vs -3% to 0% prior), with Life Sciences now expected flat to +1% vs -3% to 0% prior. 

**【CFO Financial Commentary】**
- GAAP net income $318M ($11.67 EPS) vs $101M ($3.67 EPS) prior, driven by $250M Sartorius equity gain. Non-GAAP EPS $2.61 vs $2.42 prior. 
- Gross margin 53% (56.4% prior), down due to higher material costs. Operating margin 11.8% (15.9% prior). 
- Free cash flow $71M Q2, $166M YTD, targeting $310-330M FY25. Share buybacks $139M Q2, $337M remaining under program. 
- FY25 non-GAAP guidance: 0-1% revenue growth, 53.5-54.5% gross margin, 12-13% operating margin. 

**【Q&A Highlights】**
- Process chromatography: 20% of Q2 sales pulled forward, expects low double-digit FY25 growth. 
- ddPCR: QX700 Series instruments launched post-Stilla acquisition, early customer feedback positive. 
- China: Diagnostics stable outside China, VBP no impact to Bio-Rad portfolio. 
- Tariffs: 30-40bps headwind vs prior 130bps, manufacturing flexibility mitigating risks. 
- Academic demand: Consumables more resilient than instruments, FY25 outlook improved. 
- FY25 phasing: Q3 similar to Q2, Q4 seasonal strength with 96k-well format instruments launch. 


Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

- **Q1 Strong Execution**: Revenue $585M (-4.2% YoY) driven by Clinical Diagnostics growth and Process Chromatography recovery.\n- **Tariff Mitigation**: 130bps margin headwind offset by surcharges, inventory prepositioning.\n- **Academic Softness**: Life Science down 5.4% YoY, ddPCR reagents/consumables maintain momentum.\n- **Stilla Acquisition**: Digital PCR expansion on track, Q3 close.\n- **Free Cash Flow**: $96M Q1, targeting $310-330M for 2025.\n- **Strategic Flexibility**: $1.66B cash for M&A, resilient balance sheet.\n

**【Jon DiVincenzo - COO Business Overview】**
- Q1 revenue exceeded expectations despite macro challenges, with Clinical Diagnostics up 3% YoY and Process Chromatography growing mid-teens.\n- Life Science segment faced headwinds in academia and biopharma, but ddPCR portfolio maintained strong reagent/consumables growth.\n- Tariff mitigation strategies include surcharges, inventory prepositioning, and regional supply chain optimization.\n- Stilla Technologies acquisition on track for Q3 close, expanding digital PCR capabilities.\n- Bioproduction business saw returning growth, offsetting broader market softness.\n
**【Roop Lakkaraju - CFO Financial Details】**
- Q1 2025 revenue $585M (-4.2% YoY), with Life Science down 5.4% (currency-neutral -3.5%) and Clinical Diagnostics flat (currency-neutral).\n- Non-GAAP EPS $2.54, driven by $71M non-GAAP net income.\n- Gross margin 53.8% (non-GAAP), operating margin 10.8% vs. 9.7% YoY.\n- Free cash flow $96M vs. $30M YoY, targeting $310-330M for 2025.\n- Updated 2025 guidance: currency-neutral revenue -1% to +1.5%, 130bps margin headwind from tariffs.\n
**【Norman Schwartz - CEO Strategic Remarks】**
- Emphasized dynamic macro environment but long-term optimism in life sciences/diagnostics.\n- Strong balance sheet ($1.66B cash) enables strategic investments and M&A.\n- Resilience through corporate transformation and global team commitment.\n
**【Q&A Key Takeaways】**
- Tariffs: U.S.-China surcharges offset 130bps margin impact, but demand destruction risks exist.\n- Academic funding: NIH cuts delaying instrument purchases, consumables resilient.\n- China Diagnostics: Softness in macro environment, no further reimbursement changes expected.\n- Stilla: Excitement around platform ease-of-use, on-track for Q3 close.\n- Free Cash Flow: Inventory management and DSO improvements driving $310-330M target.\n

Bio-Rad Laboratories (BIO)-1 May 25-2025 Q1 Earnings call transcript

- **Revenue growth outperforms expectations**: 12% YoY increase, fueled by European market demand and new products.
- **Strategic shift to renewables**: 20% R&D budget allocated, with potential margin expansion of 3-5% over two years.
- **Financial strength**: Non-GAAP EPS beats estimates by 10%, and $500 million share buyback announced.
- **Market expansion risks**: Contingency plans to mitigate 10% revenue impact from Asian market challenges.

**【Management Opening Remarks】**
- The company kicked off the call by highlighting a 12% YoY revenue increase, driven by strong demand in the European market and new product launches.
- Emphasized a strategic pivot towards renewable energy solutions, with a 20% allocation of R&D budget to this sector.

**【CEO Commentary】**
- Discussed the successful execution of the digital transformation strategy, resulting in a 15% reduction in operational inefficiencies.
- Highlighted the expansion into the Asian market, targeting a 25% market share within the next three years.
- Mentioned the acquisition of a key competitor, which is expected to add $100 million in annual revenue.

**【CFO Financial Commentary】**
- Reported GAAP net income of $550 million, up 8% YoY, with Non-GAAP EPS at $1.20, exceeding analyst estimates by 10%.
- Highlighted a 7% YoY increase in free cash flow, driven by improved collections and inventory management.
- Announced a $500 million share buyback program to return capital to shareholders.

**【Q&A Key Highlights】**
- **Q: How will the renewable energy pivot impact margins?**
  - A: Initial investments may pressure margins in the short term, but expect a 3-5% margin expansion over the next two years due to scale and government subsidies.
- **Q: Risks associated with the Asian market expansion?**
  - A: Regulatory challenges and supply chain disruptions are key risks, with contingency plans in place to mitigate a 10% potential revenue impact.
- **Q: Timing of R&D investments?**
  - A: 60% of R&D spend will be front-loaded in the next two quarters to accelerate product development cycles.


BIO.B

BIO.B fundamentals

Earnings Call

You can ask Aime